Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice
The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV) variants has been associated with the transmission and pathogenicity of COVID-19. Therefore, exploring the optimal immunisation strategy to improve the broad-spectrum cross-protection ability of COVID-...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1142394/full |
| _version_ | 1797870555474427904 |
|---|---|
| author | Xingxing Li Jingjing Liu Jingjing Liu Wenjuan Li Qinhua Peng Miao Li Zhifang Ying Zelun Zhang Xinyu Liu Xiaohong Wu Danhua Zhao Lihong Yang Shouchun Cao Yanqiu Huang Leitai Shi Hongshan Xu Yunpeng Wang Guangzhi Yue Yue Suo Jianhui Nie Weijin Huang Jia Li Yuhua Li |
| author_facet | Xingxing Li Jingjing Liu Jingjing Liu Wenjuan Li Qinhua Peng Miao Li Zhifang Ying Zelun Zhang Xinyu Liu Xiaohong Wu Danhua Zhao Lihong Yang Shouchun Cao Yanqiu Huang Leitai Shi Hongshan Xu Yunpeng Wang Guangzhi Yue Yue Suo Jianhui Nie Weijin Huang Jia Li Yuhua Li |
| author_sort | Xingxing Li |
| collection | DOAJ |
| description | The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV) variants has been associated with the transmission and pathogenicity of COVID-19. Therefore, exploring the optimal immunisation strategy to improve the broad-spectrum cross-protection ability of COVID-19 vaccines is of great significance. Herein, we assessed different heterologous prime-boost strategies with chimpanzee adenovirus vector-based COVID-19 vaccines plus Wuhan-Hu-1 (WH-1) strain (AdW) and Beta variant (AdB) and mRNA-based COVID-19 vaccines plus WH-1 strain (ARW) and Omicron (B.1.1.529) variant (ARO) in 6-week-old female BALB/c mice. AdW and AdB were administered intramuscularly or intranasally, while ARW and ARO were administered intramuscularly. Intranasal or intramuscular vaccination with AdB followed by ARO booster exhibited the highest levels of cross-reactive IgG, pseudovirus-neutralising antibody (PNAb) responses, and angiotensin-converting enzyme-2 (ACE2)-binding inhibition rates against different 2019-nCoV variants among all vaccination groups. Moreover, intranasal AdB vaccination followed by ARO induced higher levels of IgA and neutralising antibody responses against live 2019-nCoV than intramuscular AdB vaccination followed by ARO. A single dose of AdB administered intranasally or intramuscularly induced broader cross-NAb responses than AdW. Th1-biased cellular immune response was induced in all vaccination groups. Intramuscular vaccination-only groups exhibited higher levels of Th1 cytokines than intranasal vaccination-only and intranasal vaccination-containing groups. However, no obvious differences were found in the levels of Th2 cytokines between the control and all vaccination groups. Our findings provide a basis for exploring vaccination strategies against different 2019-nCoV variants to achieve high broad-spectrum immune efficacy. |
| first_indexed | 2024-04-10T00:29:19Z |
| format | Article |
| id | doaj.art-ed4ce87f1c364ac099e43b924d0726bd |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T00:29:19Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-ed4ce87f1c364ac099e43b924d0726bd2023-03-15T04:49:09ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.11423941142394Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in miceXingxing Li0Jingjing Liu1Jingjing Liu2Wenjuan Li3Qinhua Peng4Miao Li5Zhifang Ying6Zelun Zhang7Xinyu Liu8Xiaohong Wu9Danhua Zhao10Lihong Yang11Shouchun Cao12Yanqiu Huang13Leitai Shi14Hongshan Xu15Yunpeng Wang16Guangzhi Yue17Yue Suo18Jianhui Nie19Weijin Huang20Jia Li21Yuhua Li22Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Respiratory Virus Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of HIV/AIDS and Sex-transmitted Virus Vaccines, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of HIV/AIDS and Sex-transmitted Virus Vaccines, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaThe ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV) variants has been associated with the transmission and pathogenicity of COVID-19. Therefore, exploring the optimal immunisation strategy to improve the broad-spectrum cross-protection ability of COVID-19 vaccines is of great significance. Herein, we assessed different heterologous prime-boost strategies with chimpanzee adenovirus vector-based COVID-19 vaccines plus Wuhan-Hu-1 (WH-1) strain (AdW) and Beta variant (AdB) and mRNA-based COVID-19 vaccines plus WH-1 strain (ARW) and Omicron (B.1.1.529) variant (ARO) in 6-week-old female BALB/c mice. AdW and AdB were administered intramuscularly or intranasally, while ARW and ARO were administered intramuscularly. Intranasal or intramuscular vaccination with AdB followed by ARO booster exhibited the highest levels of cross-reactive IgG, pseudovirus-neutralising antibody (PNAb) responses, and angiotensin-converting enzyme-2 (ACE2)-binding inhibition rates against different 2019-nCoV variants among all vaccination groups. Moreover, intranasal AdB vaccination followed by ARO induced higher levels of IgA and neutralising antibody responses against live 2019-nCoV than intramuscular AdB vaccination followed by ARO. A single dose of AdB administered intranasally or intramuscularly induced broader cross-NAb responses than AdW. Th1-biased cellular immune response was induced in all vaccination groups. Intramuscular vaccination-only groups exhibited higher levels of Th1 cytokines than intranasal vaccination-only and intranasal vaccination-containing groups. However, no obvious differences were found in the levels of Th2 cytokines between the control and all vaccination groups. Our findings provide a basis for exploring vaccination strategies against different 2019-nCoV variants to achieve high broad-spectrum immune efficacy.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1142394/fullheterologous prime-boostChAdTS-SARCoVintramuscularintranasalSARS-COV-2 variants |
| spellingShingle | Xingxing Li Jingjing Liu Jingjing Liu Wenjuan Li Qinhua Peng Miao Li Zhifang Ying Zelun Zhang Xinyu Liu Xiaohong Wu Danhua Zhao Lihong Yang Shouchun Cao Yanqiu Huang Leitai Shi Hongshan Xu Yunpeng Wang Guangzhi Yue Yue Suo Jianhui Nie Weijin Huang Jia Li Yuhua Li Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice Frontiers in Immunology heterologous prime-boost ChAdTS-S ARCoV intramuscular intranasal SARS-COV-2 variants |
| title | Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice |
| title_full | Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice |
| title_fullStr | Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice |
| title_full_unstemmed | Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice |
| title_short | Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice |
| title_sort | heterologous prime boost immunisation with mrna and adc68 based 2019 ncov variant vaccines induces broad spectrum immune responses in mice |
| topic | heterologous prime-boost ChAdTS-S ARCoV intramuscular intranasal SARS-COV-2 variants |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1142394/full |
| work_keys_str_mv | AT xingxingli heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT jingjingliu heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT jingjingliu heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT wenjuanli heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT qinhuapeng heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT miaoli heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT zhifangying heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT zelunzhang heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT xinyuliu heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT xiaohongwu heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT danhuazhao heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT lihongyang heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT shouchuncao heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT yanqiuhuang heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT leitaishi heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT hongshanxu heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT yunpengwang heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT guangzhiyue heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT yuesuo heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT jianhuinie heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT weijinhuang heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT jiali heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice AT yuhuali heterologousprimeboostimmunisationwithmrnaandadc68based2019ncovvariantvaccinesinducesbroadspectrumimmuneresponsesinmice |